T-Cell Exhaustion: Can We Overcome It in Cancer?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

T Cell Exhaustion

Tumor Microenvironment

Overcoming T-Cell Dysfunction

Approved Checkpoint Inhibitors as of June 2018

Tumor Types Where PD-1/PD-L1 Inhibitors Are Approved as of June 2018

Barriers to Overcoming T-Cell Dysfunction

Co-Inhibitory and Co-Stimulatory Molecules

Caution in Developing New Molecules

New Immune Checkpoint Targets

Anti-LAG-3 Antibodies in Development

Cytokines

NKTR-214

CD47

Costimulatory Molecules

Other Approaches

HDAC Inhibitors

Further Approaches

Concluding Remarks

Abbreviations

Abbreviations (cont)